Absorption of Transdermal Vitamins in Post Bariatric Surgery Patients

Sponsor
University of Florida (Other)
Overall Status
Completed
CT.gov ID
NCT03360435
Collaborator
(none)
99
1
42.7
2.3

Study Details

Study Description

Brief Summary

Patients undergoing bariatric surgery often develop new vitamin and/or mineral deficiencies or exacerbate prior deficiencies after surgery. Several bariatric supplement products exist including oral tablets and transdermal patches. The purpose of this study is to observe the concentrations of serum micronutrients and determine how many deficiencies develop in patients who use a transdermal patch.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Patch MD MultiVitamin Plus patch

Detailed Description

Patients will undergo either a sleeve gastrectomy or gastric bypass procedure. All patients enrolled will have previously chosen to use the Patch MD MultiVitamin Plus patch for vitamin and mineral supplementation versus oral or other dosage forms of vitamins after surgery. A conversation between the patient and provider will occur first during a pre operative appointment, at which time the patient will be presented with the option to use oral vitamins or the Patch MD MultiVitamin Plus patch after surgery. Only if the patient chooses the patch will he/she be made aware of the study and recruited. Pre operative blood draws will be used to determine baseline micronutrient serum concentrations and existing deficiencies. The Gastrointestinal Symptom Rating Scale (GSRS) will be used pre operatively to determine baseline gastrointestinal symptoms. Post operative blood draws and GSRS data will be collected at 3 months, 6 months, and 1 year after surgery.

Study Design

Study Type:
Observational
Actual Enrollment :
99 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Absorption of Transdermal Vitamins in Post Bariatric Surgery Patients
Actual Study Start Date :
Dec 15, 2017
Actual Primary Completion Date :
Jul 7, 2021
Actual Study Completion Date :
Jul 7, 2021

Arms and Interventions

Arm Intervention/Treatment
Participants with transdermal patches

All study subjects will belong to the same group. This group will undergo bariatric surgery and will use a transdermal patch for vitamin and mineral supplementation post operatively. The transdermal patch will be the Patch MD MultiVitamin Plus patch

Dietary Supplement: Patch MD MultiVitamin Plus patch
The transdermal patch contains vitamins A, D, E, K2, C, thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, cyanocobalamin, calcium, iron, phosphorous, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, potassium, chloride, and boron.

Outcome Measures

Primary Outcome Measures

  1. Percentage of subjects with deficiencies [1 year]

    The primary end point is the percentage of participants who have two or more deficiencies of vitamins B1, B6, B12, folate, D, zinc, calcium, copper, and iron one year after bariatric surgery after using the Patch MD™ MultiVitamin Plus transdermal patch for supplementation.

Secondary Outcome Measures

  1. Thiamine [1 year]

    The average decrease in the serum concentration among all subjects

  2. Pyridoxine [1 year]

    The average decrease in the serum concentration among all subjects

  3. Methylcobalamin [1 year]

    The average decrease in the serum concentration among all subjects

  4. Vitamin D [1 year]

    The average decrease in the serum concentration among all subjects

  5. Folate [1 year]

    The average decrease in the serum concentration among all subjects

  6. Zinc [1 year]

    The average decrease in the serum concentration among all subjects

  7. Calcium [1 year]

    The average decrease in the serum concentration among all subjects

  8. Copper [1 year]

    The average decrease in the serum concentration among all subjects

  9. Iron [1 year]

    The average decrease in the serum concentration among all subjects

  10. Ferritin [1 year]

    The average decrease in the serum concentration among all subjects

  11. Parathyroid hormone [1 year]

    The average decrease in the serum concentration among all subjects

  12. Total iron binding capacity [1 year]

    The average decrease among all subjects

  13. Constipation syndrome [1 year]

    The average increase among all subjects using the Gastrointestinal Symptom Rating Scale. For constipation syndrome, three symptoms (constipation, hard stools, feeling of incomplete evacuation) will each be measured on a seven point Likert scale (0=no symptom, 6=most severe symptom). The three values will be averaged to provide one value which will represent constipation syndrome.

  14. Diarrhea syndrome [1 year]

    The average increase among all subjects using the Gastrointestinal Symptom Rating Scale. For diarrhea syndrome, three symptoms (diarrhea, loose stools, urgent need for defecation) will each be measured on a seven point Likert scale (0=no symptom, 6=most severe symptom). The three values will be averaged to provide one value which will represent diarrhea syndrome.

  15. Indigestion syndrome [1 year]

    The average increase among all subjects using the Gastrointestinal Symptom Rating Scale. For indigestion syndrome, five symptoms (nausea, stomach rumbling, feeling bloated, burping, and passing gas) will each be measured on a seven point Likert scale (0=no symptom, 6=most severe symptom). The five values will be averaged to provide one value which will represent indigestion syndrome.

  16. Acid reflux syndrome [1 year]

    The average increase among all subjects using the Gastrointestinal Symptom Rating Scale. For acid reflux syndrome, two symptoms (heart burn and acid reflux) will each be measured on a seven point Likert scale (0=no symptom, 6=most severe symptom). The two values will be averaged to provide one value which will represent acid reflux syndrome.

  17. Abdominal pain syndrome [1 year]

    The average increase among all subjects using the Gastrointestinal Symptom Rating Scale. For abdominal pain syndrome, two symptoms (stomach ache and hunger pains) will each be measured on a seven point Likert scale (0=no symptom, 6=most severe symptom). The two values will be averaged to provide one value which will represent abdominal pain syndrome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Candidates for a sleeve gastrectomy or gastric bypass surgery

  2. Willingness and ability to provide informed consent in English

  3. Commitment to the 1 year study period

Exclusion Criteria:
  1. Planned bariatric revision surgery

  2. Patients with a left ventricular assistance device

  3. Known End Stage Renal Disease

  4. Known mutation in methylenetetrahydrofolate reductase (MTHFR) gene

  5. Medical conditions requiring vitamin and mineral supplementation

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Florida Gainesville Florida United States 32611

Sponsors and Collaborators

  • University of Florida

Investigators

  • Principal Investigator: Jeffrey E Friedman, MD, University of Florida

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Florida
ClinicalTrials.gov Identifier:
NCT03360435
Other Study ID Numbers:
  • IRB201701809
First Posted:
Dec 4, 2017
Last Update Posted:
Jul 9, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 9, 2021